ADC Therapeutics Sees Continued Decrease In Total Operating Expenses In FY23 And FY24 As Compared to FY22; Expected Cash Runway Into Middle of 2025
ADC Therapeutics預計,與22財年相比,23財年和24財年的總運營支出將繼續減少;預計現金流將持續到2025年中期
ADC Therapeutics Sees Continued Decrease In Total Operating Expenses In FY23 And FY24 As Compared to FY22; Expected Cash Runway Into Middle of 2025
ADC Therapeutics預計,與22財年相比,23財年和24財年的總運營支出將繼續減少;預計現金流將持續到2025年中期
使用瀏覽器的分享功能,分享給你的好友吧